Given the critical role of the PI3K/Akt/mTOR signaling pathway in cancer biology and the immunostimulatory effect of PI3K/Akt/mTOR inhibitors on DC-tumor hybrids, combination therapy may represent a promising and novel cancer vaccine with enhanced clinical impact. This evidence concerns the gene MTOR and cancer.